Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Article uri icon

Overview

authors

  • Ravandi, Farhad
  • Ritchie, Ellen K.
  • Sayar, Hamid
  • Lancet, Jeffrey E
  • Craig, Michael D
  • Vey, Norbert
  • Strickland, Stephen A
  • Schiller, Gary J
  • Jabbour, Elias
  • Pigneux, Arnaud
  • Horst, Heinz-August
  • Récher, Christian
  • Klimek, Virginia M
  • Cortes, Jorge E
  • Carella, Angelo-Michele
  • Egyed, Miklos
  • Krug, Utz
  • Fox, Judith A
  • Craig, Adam R
  • Ward, Renee
  • Smith, Jennifer A
  • Acton, Gary
  • Kantarjian, Hagop M
  • Stuart, Robert K

publication date

  • May 24, 2018

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia, Myeloid, Acute

Identity

PubMed Central ID

  • PMC6278965

Scopus Document Identifier

  • 85055851886

Digital Object Identifier (DOI)

  • 10.3324/haematol.2018.191361

PubMed ID

  • 29794146

Additional Document Info

volume

  • 103

issue

  • 11